Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyaluronic acid added to levobupivacaine pudendal nerve block for pudendal neuralgia
ACTRN12617001378314Phase 3Recruiting
- Sponsor
- Women's Health & Research Institute of Australia
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of hyaluronic acid and levobupivacaine in pudendal neuralgia (PN) (2 arms), sponsored by Women's Health & Research Institute of Australia. Primary endpoint: Pain relief using Brief Pain Inventory - Short Form. Started May 2018; status: recruiting.
02
Drugs
hyaluronic acidlevobupivacaine
03
Conditions
pudendal neuralgia (PN)
Beyond the preview
Go deeper on ACTRN12617001378314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001378314.